DE

latest development

News & Events

News & Events

Press Releases

Vidac Pharma advances cancer metabolism inhibitor VDA-1275 into preclinical IND-enabling studies

Monday, April 29, 2024
London (UK), April 29, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announced it...
Read More...

Vidac Pharma secures approval for next phase of clinical study into lead asset into CTCL

Monday, March 11, 2024
London (UK), March 11, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announced it has...
Read More...

Vidac Pharma presents high efficacy in multiple solid tumor models for its next-generation cancer drug candidate and synergy with standard-of-care treatment in liver cancer organoids

Tuesday, February 20, 2024
London (UK), February 19, 2024, 7:30 am CET – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today...
Read More...

Vidac Pharma receives issue notification from US patent office for manufacturing of lead asset VDA-1102

Monday, February 12, 2024
London ( UK), February 12, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking new way of treating cancer, today announces...
Read More...

Vidac Pharma to present company at Sachs European Healthtech CEO Forum with latest developments of revolutionary approach to treat cancer

Monday, February 12, 2024
London (UK), February 12, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking new way of treating cancer, today announces...
Read More...

Vidac Pharma reports favorable data from Phase 2a interim analysis for its lead asset VDA-1102 in CTCL

Monday, January 29, 2024
London ( UK), January 29, 2024 – – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking new way of treating cancer, today announces...
Read More...

Vidac Pharma sees growing recognition of its innovative approach to fight cancer

Monday, January 22, 2024
London (UK), January 22, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking new way of treating cancer, at an international...
Read More...

Vidac Pharma to present strategy and upcoming milestones to leading investors in Switzerland in January

Monday, January 15, 2024
London (UK), January 15, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking new way of treating cancer, will present its...
Read More...